Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Published byClifford Newton Modified over 9 years ago

Similar presentations

Presentation on theme: "Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer."— Presentation transcript:

1 Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer patients. P values were calculated using logrank test. A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples). C. RASSF1A methylated (M) versus unmethylated (U) (all samples). D. EGFR mutated (M) versus wild type (WT) [all samples]. E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples). F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma). G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma). H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma).

2 A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). Months P=0.64

3 Months P=0.38 B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples).

4 Months P=0.99 C. RASSF1A methylated (M) versus unmethylated (U) (all samples).

5 D. EGFR mutated (M) versus wild type (WT) [all samples]. Months P=0.64

6 Months P=0.63 E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples).

7 Months P=0.74 F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma)

8 Months P=0.93 G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma).

9 Months P=0.09 H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma).

Download ppt "Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer."

Similar presentations

Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.

Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.
TCGA(The cancer genome atlas) catalogue genetic mutations responsible for cancer, using genome sequencing and bioinformatics The TCGA is sequencing the.

TCGA(The cancer genome atlas) catalogue genetic mutations responsible for cancer, using genome sequencing and bioinformatics The TCGA is sequencing the.
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
EGFR gene mutation testing in NSCLC

EGFR gene mutation testing in NSCLC
Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.

Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.
Supplementary Figure 1. Somatic mutation spectrum # Substitutions # Substitutions per Mb b c a Repeats Pseudogenes Whole genome Splice sites Non-coding.

Supplementary Figure 1. Somatic mutation spectrum # Substitutions # Substitutions per Mb b c a Repeats Pseudogenes Whole genome Splice sites Non-coding.
2015/2016. 1.NON-SMALL CELL LUNG CANCER (NSCLC) 1.1 Adenocarcinomas are often found in an outer area of the lung. 1.2 Squamous cell carcinomas are usually.

2015/ NON-SMALL CELL LUNG CANCER (NSCLC) 1.1 Adenocarcinomas are often found in an outer area of the lung. 1.2 Squamous cell carcinomas are usually.
ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.

ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.
Cell lineStatus FGFR1 DMS-114Gene amplification NCI-H520Gene amplification NCI-H1581Gene amplification FGFR2 NCI-H716Gene amplification KATO-IIIGene amplification.

Cell lineStatus FGFR1 DMS-114Gene amplification NCI-H520Gene amplification NCI-H1581Gene amplification FGFR2 NCI-H716Gene amplification KATO-IIIGene amplification.
Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）
YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.

YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.
MOLECULAR DIAGNOSTICS IN ONCOLOGY Dr. Sergey Kovalenko.

MOLECULAR DIAGNOSTICS IN ONCOLOGY Dr. Sergey Kovalenko.
Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;
Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A
Main Figures and Tables

Main Figures and Tables
Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.
Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.
Hallett, et al., - Supplementary Figure 1

Hallett, et al., - Supplementary Figure 1

Similar presentations

Ads by Google